Last checked at 23 Jul 2018 12:53
Monday broker round-up
(Sharecast News) - Hargreaves Lansdown: Jefferies downgrades to underperform with a target price of 1,650p.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Beximco Pharma Share News (BXP)
BXP Share
Price
BXP Share
News
BXP Share
Chat
BXP Share
Trades3
BXP
Live RNS
BXP Share
Charts
BXP Level 2
Console
BXP Live
Share Price
BXP Broker
Ratings
BXP Directors
Deals
BXP Financial
Diary
BXP
Fundamentals
BXP Short
Positions
BXP
Media
Beximco Pharma Information
Share Price Information for Beximco Pharma (BXP)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
37.50
Bid:
36.00
Ask:
39.00
Change:
1.00 (2.74%)
Spread:
3.00 (8.333%)
Open:
37.00
High:
37.50
Low:
37.00
Prev. Close:
36.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Beximco gets FDA approval for generic anti-allergy drug
Wed, 24th Apr 2019 15:41
(Sharecast News) - Beximco Pharmaceuticals announced on Wednesday that it has received US Food and Drug Administration (FDA) approval for its cyproheptadine hydrochloride tablet 4mg anti-allergy drug, which is a generic equivalent to 'Periactin' 4mg tablets from Merck and Company.The AIM-traded firm described the drug as an antihistamine, used to relieve allergy symptoms such as hives, watery eyes, sneezing and itchy eyes or nose.It said the total US market for cyproheptadine tablets was approximately $16m in 2018.In August 2016, Beximco became the first Bangladeshi pharmaceutical company to export medicine to the US market, following the approval of its oral solid dosage facility by the FDA in June 2015.Cyproheptadine was now Beximco's seventh abbreviated new drug application approved for the US market."Cyproheptadine is our seventh product approved for the US market, and with our recent acquisition of eight ANDAs from Sandoz, our US portfolio now stands at 15 products," said Beximco Pharmaceuticals managing director Nazmul Hassan."This approval gives us further confidence that our strategic focus and growing pipeline will strengthen our presence in the world's largest pharma market."
More News
27 Jan 2017 10:45
Beximco profits rise as it begins US exports
(ShareCast News) - Bangladeshi generic pharmaceutical products and active pharmaceutical ingredients manufacturer Beximco Pharmaceuticals announced its unaudited financial results for the six months to 31 December on Friday. The AIM-traded company said net sales increased by 13.6% to BDT 7,630.6m or
Read more25 Jan 2017 16:10
Beximco Pharma partners with BioCare in Malaysia
(ShareCast News) - Generic pharmaceutical products manufacturer Beximco Pharmaceuticals announced the creation of a joint venture with BioCare Manufacturing, based in Malaysia, as the company's first overseas manufacturing collaboration on Wednesday. The AIM-traded firm said that under the terms of
Read more21 Nov 2016 10:49
20 Oct 2016 11:01
Beximco sales grow in first half
(ShareCast News) - Generic pharmaceutical products and active ingredients manufacturer Beximco Pharmaceuticals posted audited results for the half year to 30 June on Thursday, with net sales growing by 13.1% to BDT 7.07bn. The AIM-traded firm's export sales grew by 5.3%, and domestic market sales in
Read more17 Jun 2016 15:21
Beximco makes historic drug shipment to Kuwait
(ShareCast News) - Generic pharmaceutical manufacturer Beximco announced on Friday that it has commenced the export of pharmaceuticals to Kuwait. The AIM-traded firm said it marks the first time a Bangladeshi pharmaceutical company has launched products in any Gulf member country under the Gulf Coop
Read more17 Jun 2016 07:21
24 Jun 2015 06:53